Owkin is an AI biotechnology company transforming healthcare with artificial intelligence. By combining advanced biology, machine learning, and privacy-first technology, Owkin accelerates drug discovery and personalized medicine. Through AI copilots and global collaborations, the company uncovers disease insights, turning complex data into actionable solutions and life-saving breakthroughs.
Owkin makes use of the latest technology in machine learning to completely change the way medical research and healthcare decisions are made. It is the transforming of fragmented and complicated data into insights that are innovation-driving, made possible by the collaboration of global institutions across borders with security and privacy protection.
The company creates a partnership between researchers, clinicians, and industrial counterparts to speed up discovery, trial of new drugs and increase accuracy of diagnostics, thus, allowing the healthcare and therapeutic development to become even more sophisticated and driven by data.
| Legal Name | Owkin, Inc |
| Headquarters | Dual Headquarters, Paris and New York |
| Business Model | B2B |
| Founding Date | 2016 |
| No. of Employees | Approx. 467 (As of 2025) |
Owkin offers AI diagnosis and research solutions, including MSIntuit® CRC, MSIntuit® BTC, MSIntuit® EC, MSIntuit® GC, RlapsRisk® BC, BRCAura RUO, TLS Detect, Destra workflow platform, and IHC Solutions. Its services include AI diagnostics, biomarker screening, outcome prediction, clinical trial optimization, and pharma collaboration tools.
| Thomas Clozel, MD | Co-founder & Chief Executive Officer |
| Alban de la Sablière | Chief Operating Officer |
| Eric Durand, PhD | Chief Research & Technology Officer |
| Graeme Bell | Chief Financial Officer |
| Darius Meadon | Chief Marketing Officer |
| Caroline Hoffmann | Chief Medical Officer |
| Agathe Arlotti | Senior Vice President, Partnerships |
| Mariabrisa Olivares | Chief People Officer |
| Jean-Frédéric Petit-Nivard | Chief Commercial Officer |
| Meriem Sefta, PhD | Chief Diagnostics Officer |
Owkin's revenue model is primarily based on the combination of strategic partnerships with worldwide pharmaceuticals, collaborations depending on milestones achieved, and the licensing of their technology.
Client Segments: Large pharmaceutical companies, biotechnology firms, academic research institutions, and clinical research organizations.
Target Companies: Global biopharmaceutical companies, research labs, and clinical research organizations seeking AI-driven healthcare innovation.
Target Geography: Global, with strong adoption in North America and Europe, and expanding presence internationally.